Tag: berotralstat
BioCryst Receives UK Approval of ORLADEYO™ (berotralstat), First Oral, Once-daily Therapy...
RESEARCH TRIANGLE PARK, N.C., May 12, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the United Kingdom’s...
BioCryst Announces Approval of Japanese NHI Price Listing of ORLADEYO™ (berotralstat)...
—ORLADEYO is the first and only approved prophylactic therapy for HAE in Japan— —NHI price listing triggers $15 million milestone payment to...